In preparing amorphous solid dispersions (ASDs) to increase bioavailability, Eudragit L100 has proven a useful excipient, due to its favorable impact on ASD physical stability and dissolution performance. However, when Eudragit L100 is spray-dried, high-aspect-ratio filaments can form, which negatively impact downstream ASD performance and dosage form manufacturability. This paper describes a study of how such filaments form and a particle-design space that identifies key processing parameters that can be used to mitigate the risk of filament formation. To learn more, please read our publication.
Latest content